No scientist named “Jordan Grant” and no Dutch scientific journal called “Next Level” can be independently traced to the genetic-engineering claims built around them. The citation collapses at the point where it should become most verifiable: the source itself.
What remains after removing the fabricated authority is more complicated than either side of the usual argument admits. Genes are real. Genetic engineering is real. CRISPR is real. So are gene patents, corporate concentration in agriculture, legitimate questions about who controls biological technologies, and genuine ethical failures in the history of genetic research. The deception is not that modern biology secretly collapsed. It is the construction of a dramatic narrative in which legitimate scientific controversies are made to depend on sources that cannot be independently verified.
The “Collapse of Gene Theory” Never Happened
There is an important distinction here that sensational accounts routinely erase. Modern genetics has moved far beyond the simplistic idea that DNA is a rigid blueprint in which every trait is encoded as a single instruction, but abandoning that metaphor is not the same thing as abandoning genes. The Human Genome Project, completed in 2003, produced the first reference sequence of the human genome and transformed the ability of researchers to identify, compare, and study genetic variation. Modern biology has subsequently shown that gene expression depends on regulatory networks, cellular context, developmental history, environmental conditions, epigenetic mechanisms, and interactions among genes themselves. That is not a collapse of genetics. It is what scientific progress looks like when an initially useful model becomes more sophisticated.
The deeper mistake is treating the complexity of biology as evidence that biology has no underlying structure. Researchers can sequence DNA, identify mutations, measure gene expression, manipulate particular sequences, and observe the resulting biological effects precisely because genetic mechanisms are experimentally accessible. The fact that genes interact with one another and with their environment makes prediction harder, but it does not make the genes imaginary. If anything, modern molecular biology is remarkable precisely because scientists can now watch parts of this machinery operating at levels of detail that were unimaginable a century ago.
CRISPR Is Powerful Because It Is Precise Enough to Be Regulated
CRISPR does not deserve either of the two caricatures usually assigned to it. It is neither an omnipotent molecular editing machine capable of rewriting biology without consequences nor a crude technology that scientists cannot control. Like every powerful biological tool, it has limitations, including off-target editing, unintended genomic changes, delivery problems, immune responses, and questions about long-term effects. Those risks are precisely why clinical applications require extensive testing and regulatory review.
And this is no longer purely theoretical. In December 2023, the U.S. Food and Drug Administration approved Casgevy, a CRISPR/Cas9-based therapy for sickle cell disease, later extending its approval to transfusion-dependent beta thalassemia. The significance is not that regulatory approval proves CRISPR is universally safe. It proves something more specific and more important: a gene-editing technology can be developed into a therapeutic product, subjected to clinical evidence and regulatory scrutiny, and authorized for a defined medical use. The technology remains imperfect. That is precisely why the scientific literature continues to study how to make it safer and more predictable.
Gene Patents Are a Real Controversy. The Human Genome Is Not a Corporate Monopoly.
This is where the legitimate political argument begins. Patents on biological inventions can affect who develops technologies, who can commercialize them, how much access costs, and how much control private companies exercise over agricultural or medical innovations. Those questions deserve serious scrutiny. But the claim that corporations can simply patent naturally occurring human genes and thereby own the corresponding genetic material is not an accurate description of current U.S. law.
In Association for Molecular Pathology v. Myriad Genetics, the U.S. Supreme Court ruled in 2013 that a naturally occurring DNA segment is not patent-eligible merely because it has been isolated from the rest of the genome. The Court distinguished naturally occurring DNA from laboratory-created DNA such as complementary DNA, meaning the legal landscape is more nuanced than either “genes cannot be patented” or “companies own the human genome.” The important point is that the nightmare scenario of a corporation simply acquiring exclusive ownership of naturally occurring human genes was already rejected by the highest court in the United States. Patent law still matters enormously. It simply matters in a more complicated way than the conspiracy version suggests.
GMOs Are Not “Radiation and Chemical Roulette”
Genetic engineering is also routinely collapsed into every other technique humans have ever used to alter crops. That is scientifically misleading. Mutation breeding, for example, has used radiation or chemical mutagens to create genetic variation in plants for decades, but that technique is not synonymous with modern genetic engineering. Conventional breeding, mutation breeding, transgenesis, and newer gene-editing approaches are different technologies with different mechanisms and different regulatory questions.
The safety question also has to be asked product by product rather than as a referendum on the word “GMO.” The World Health Organization and major scientific assessments have concluded that genetically modified foods currently on the market have not been shown to present greater risks to human health simply because they were produced using genetic engineering. One influential 2013 review by Nicolia and colleagues examined 1,783 publications, reviews, and reports concerning the safety of genetically engineered crops and found no evidence in the literature reviewed of significant hazards directly attributable to their use. That does not mean every future genetically engineered organism is automatically safe. It means safety has to be evaluated from the characteristics of the actual organism and trait, not from a blanket assumption that the technology itself makes food dangerous.
Dolly Was Real. So Was the He Jiankui Scandal.
Dolly the sheep was not a myth manufactured to sell genetic engineering. She was a real cloned mammal, born at the Roslin Institute in 1996 after researchers used somatic-cell nuclear transfer to produce an animal genetically related to the adult cell donor. Her existence became a landmark in developmental biology because it demonstrated that the nucleus of a differentiated adult cell could be used to generate an entire animal.
And the 2018 birth of gene-edited children in China was real as well, but the historical lesson is almost the opposite of the one implied by conspiracy narratives. Researcher He Jiankui announced that he had edited human embryos using CRISPR and that twin girls had subsequently been born. The experiment triggered international condemnation because of its ethical failures, scientific uncertainties, inadequate oversight, and violation of accepted standards for human-subject research. Chinese authorities later convicted He of illegal medical practice and sentenced him to prison. The episode therefore does not demonstrate that scientists secretly approved uncontrolled human genetic experimentation. It demonstrates that an individual researcher could violate established ethical and regulatory boundaries, and that the resulting breach produced an enormous scientific and institutional backlash.
What Seed Patents Actually Mean
Seed patents are another place where a genuine issue gets transformed into an absolute claim. Farmers can face legal restrictions when they purchase patented seed varieties, particularly where patent rights or contractual licensing terms restrict saving and replanting seed for subsequent seasons. That is a real economic issue, especially in agricultural systems where a small number of companies control substantial portions of particular markets.
But it is not accurate to turn those restrictions into a universal statement that farmers everywhere have been legally forbidden from saving all seed. Patent law varies by country, different forms of intellectual-property protection apply to different crops and varieties, licensing agreements differ, and non-proprietary varieties remain outside particular patent claims. The serious question is therefore not whether “all seeds are owned.” It is how intellectual-property regimes distribute power between breeders, corporations, farmers, researchers, and the public, and whether those rules strike an acceptable balance between innovation and access.
Epigenetics Did Not Destroy Genetics
Epigenetics is often presented as the scientific discovery that supposedly proved genes were a fraud. It did nothing of the kind. Epigenetics examines mechanisms that influence gene activity without changing the underlying DNA sequence, including chemical modifications and changes in the proteins associated with DNA. These mechanisms can influence which genes are expressed in particular cells and developmental contexts, and some epigenetic states can be influenced by environmental conditions.
The important word is regulation. Epigenetics adds another layer to our understanding of how genetic information is used, it does not erase the underlying sequence or eliminate genetics. Modern biology increasingly looks less like a simple instruction manual and more like a dynamic regulatory system in which DNA, proteins, cells, development, and environment interact continuously. That is a more complicated picture than the old “blueprint” metaphor. It is also a much more scientifically interesting one.
A Bigger Question Than Any Single Gene
There is a serious conversation to be had about corporate power in biotechnology. Who owns patents on engineered organisms? Who controls agricultural germplasm? Who can afford advanced gene therapies? How should regulators balance incentives for private research against public access? What happens when a technology powerful enough to treat disease is available only to people who can afford it? And how should society regulate technologies capable of altering human embryos or permanently changing inherited genetic information?
Those are not fringe questions. They are precisely the questions that become harder when the evidence is replaced by fabricated authorities and exaggerated scientific claims. A fake researcher does not strengthen an argument about corporate power. An invented journal does not expose a conspiracy. And declaring that “gene theory collapsed” does not make the legitimate debate over biotechnology any more persuasive.
The irony is that the real story is already consequential enough. Biology has reached the point where humans can read genomes, modify DNA, manufacture biological molecules, clone mammals, edit disease-causing mutations, and debate whether some forms of genetic intervention should ever be permitted. That is an extraordinary amount of power to have acquired in barely more than a century. We do not need to invent a scientific collapse to make that frightening. We need to understand who controls the technology, who benefits from it, who bears its risks, and what limits society is willing to impose.
The deception was never that genetic engineering was fake. The deception was making real science depend on evidence that wasn’t.
